Cannabidiol Market Projected to Reach $382.04 Billion by 2034

The global cannabidiol (CBD) market is poised for explosive growth, with projections estimating a valuation of $382.04 billion by 2034. Driven by a compound annual growth rate of 40.89%, the sector is benefiting from increased legal liberalization and rising consumer acceptance across the food, cosmetic, and pharmaceutical industries. This massive expansion signals a significant shift in the global hemp and cannabis landscape as manufacturers scale operations to meet burgeoning demand for non-psychoactive wellness products.

The global CBD market, valued at $16.52 billion in 2025, is expected to surge to $24.61 billion in 2026 before hitting the $382.04 billion mark by 2034. North America currently leads the sector, holding a 47.63% market share as of 2025, with the U.S. market alone expected to reach $78.74 billion by 2032. This growth is primarily fueled by the extraction of CBD from hemp and cannabis to address health concerns such as anxiety, seizures, and chronic inflammation.

Industry players are aggressively pursuing mergers and acquisitions to capture market share, highlighted by British Cannabis’s February 2024 acquisition of Goodbody Botanicals Ltd to expand its herbal wellness and cosmetic reach. Innovation is also a key driver, with companies like BASF SE entering the space; in August 2022, the firm launched ComfortBD, a skincare product utilizing certified organic industrial hemp grown in the U.S. These developments reflect a broader trend of manufacturers infusing CBD into novel food and beauty applications to meet consumer fitness and wellness goals.

The pharmaceutical segment is a critical pillar of the industry, projected to account for 36.9% of the CBD market by 2026. As the global pharmaceutical sector expands toward a $1.5 trillion valuation, the adoption of CBD for its neuroprotective and pain-relief properties is increasing, supported by government approvals for medical therapies. While the U.S. FDA is working to establish clearer regulatory pathways for food and non-food applications, the industry still faces hurdles in Asia and the Middle East, where myths regarding psychoactive effects continue to hamper market penetration.